9606 — Duality Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- HK$27.60bn
- HK$23.63bn
- CNY1.94bn
Annual cashflow statement for Duality Biotherapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Net Income/Starting Line | -202 | -1,015 |
| Depreciation | ||
| Amortisation | ||
| Non-Cash Items | 988 | 1,038 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | 25.4 | 254 |
| Change in Accounts Receivable | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Change in Other Liabilities | ||
| Other Operating Cash Flow | ||
| Cash from Operating Activities | 816 | 286 |
| Capital Expenditures | -35.9 | -31.2 |
| Purchase of Fixed Assets | ||
| Purchase / Acquisition of Intangibles | ||
| Other Investing Cash Flow Items | -42.6 | -180 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Other Investing Cash Flow | ||
| Cash from Investing Activities | -78.5 | -211 |
| Financing Cash Flow Items | -1.59 | -4.22 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 10.8 | -7.62 |
| Foreign Exchange Effects | ||
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 755 | 78 |